In HIV Research, A Race For The Cure Is Back On Track
This article was originally published in Start Up
Hopes for a vaccine or cure for HIV/AIDS have been dashed before. But recent scientific advances and greater understanding of the limits of antiretroviral drugs have reignited optimism. Just don't expect VCs to get on board.
You may also be interested in...
HIV may be effectively treated and managed with available therapies, but there is still great unmet need for a functional cure and better prevention to stop the epidemic.
There’s still money for early-stage innovation despite worries to the contrary, but total dollars for Series A financings remain about one-third fewer than during the high years of the mid-2000s, and investor syndicates are mindful of making those dollars stretch as far as possible. For the 2012 A-List, our ninth, we’ve decided to ask a fundamental question as the life science venture world goes through economic upheaval: does “Series A” mean the same thing, or conjure the same connotations, as it did when the class of 2004 made the first A-List?
Previously supported by angels and seed-stage investors, the Philadelphia-area start-up has turned to 5AM Ventures and Canaan Partners for a Series A round that will support development of HBV and HIV drug candidates.